Atropos Health has partnered with Novartis to develop an AI algorithm that speeds up the diagnosis of paroxysmal nocturnal haemoglobinuria (PNH), a rare blood disorder.
The collaboration aims to streamline patient identification and accelerate diagnosis and treatment, enhancing patient care.
Under the partnership, the healthcare data company will create and evaluate AI models to identify undiagnosed PNH patients.
The move will address the prolonged diagnostic delays due to the rarity and varied symptoms of the disease.
The AI model, designed for integration into health systems, promises to save critical time for both patients and healthcare providers.
Atropos Health will implement the AI models across its Atropos Evidence Network, integrating them at the point of care to improve outcomes.
Novartis US oncology head Rodney Gillespie said: “At Novartis, we are committed to delivering meaningful impact for patients.
“Accelerating diagnosis and treatment through AI and machine learning has the power to significantly improve patient outcomes by enabling faster access to appropriate care.
“Our collaboration with Atropos Health to develop an AI model for identifying PNH embodies this commitment as it advances precision health, potentially enabling earlier diagnosis and timely care, reducing delays that can greatly affect patients’ lives.”
The collaboration follows Atropos Health’s earlier AI model training capabilities, allowing network members to leverage AI models for clinical use.
In addition, Atropos Health is collaborating with Arcadia, a healthcare data platform, to deliver advanced precision medicine and care protocols at scale.
The partnership aims to enhance clinical decision-making with AI-powered insights, using real-world evidence and patient records to drive high-value, low-cost care.
Atropos Health CEO and co-founder Brigham Hyde said: “Building AI models tested and trained on high-quality real-world data is truly the next frontier in precision medicine.
“The accuracy of the models reduces the guesswork and patients who are able to get testing sooner provides a potentially life-changing experience.
“For providers and health systems, faster time to diagnosis and treatment equate to higher patient satisfaction.”
